ASBM Paper on Biosimilar Naming Published in the Food and Drug Law Institute’s Policy Forum
November 28, 2012
Unique names key factor to ensure patient-safety in biosimilar pathway WASHINGTON – The Food and Drug Law Institute (FDLI) Policy Forum today published a white paper on biosimilar naming authored by the Alliance for Safe Biologic Medicines (ASBM). “It’s All About the Name: What is the Imperative of Adopting Unique Names For Biologic and Biosimilar […]